Jonathan Lyne

Jonathan Lyne

Auto-generated profile, based on publicly available information

Jonathan Lyne

Division of Cardiac Electrophysiology, Beacon Hospital , Dublin

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
DKDaniel Keene
Daniel Keene
FAFrédéric Anselme
Frédéric Anselme
HBHaran Burri
Haran Burri
ÓCÓscar Cano
Óscar Cano
KCkarol curila
karol curila
ZWZachary Whinnett
Zachary Whinnett
Aims: The field of conduction system pacing (CSP) is evolving, and our aim was to obtain a contemporary picture of European CSP practice. Methods and results: A survey was devised by a European CSP Expert Group and sent electronically to cardiologists utilizing CSP. A total of 284 physicians were invited to contribute of which 171 physicians (60.2%; 85% electrophysiologists) responded. Most (77%) had experience with both His-bundle pacing (HBP) and left bundle branch area pacing (LBBAP). Pacing indications ranked highest for CSP were atrioventricular block (irrespective of left ventricular ejection fraction) and when coronary sinus lead implantation failed. For patients with left bundle branch block (LBBB) and heart failure (HF), conventional biventricular pacing remained first-line treatment. For most indications, operators preferred LBBAP over HBP as a first-line approach. When HBP was attempted as an initial approach, reasons reported for transitioning to utilizing LBBAP were: (i) high threshold (reported as >2 V at 1 ms), (ii) failure to reverse bundle branch block, or (iii) > 30 min attempting to implant at His-bundle sites. Backup right ventricular lead use for HBP was low (median 20%) and predominated in pace-and-ablate scenarios. Twelve-lead electrocardiogram assessment was deemed highly important during follow-up. This, coupled with limitations from current capture management algorithms, limits remote monitoring for CSP patients. Conclusions: This survey provides a snapshot of CSP implementation in Europe. Currently, CSP is predominantly used for bradycardia indications. For HF patients with LBBB, most operators reserve CSP for biventricular implant failures. Left bundle branch area pacing ostensibly has practical advantages over HBP and is therefore preferred by many operators. Practical limitations remain, and large randomized clinical trial data are currently lacking.

1 November 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
MJMarek Jastrzębski
Marek Jastrzębski
PFPaul Foley
Paul Foley
BCBadrinathan Chandrasekaran
Badrinathan Chandrasekaran
ZWZachary Whinnett
Zachary Whinnett
PVPugazhendhi Vijayaraman
Pugazhendhi Vijayaraman
BHBengt Herweg
Bengt Herweg
BACKGROUND: Left bundle branch area pacing (LBBAP) may be an alternative to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT). We sought to compare the acute hemodynamic and ECG effects of LBBAP, BVP, and left bundle-optimized therapy CRT (LOT-CRT) in CRT candidates with advanced conduction disease. METHODS: In this multicenter study, 48 patients with either nonspecific interventricular conduction delay (n=29) or left bundle branch block (n=19) underwent acute hemodynamic testing to determine the change in left ventricular pressure maximal first derivative (LV d P /d t max ) from baseline atrial pacing to BVP, LBBAP, or LOT-CRT. RESULTS: Atrioventricular-optimized increases in LV d P /d t max for LOT-CRT (mean, 25.8% [95% CI, 20.9%–30.7%]) and BVP (26.4% [95% CI, 20.2%–32.6%]) were greater than unipolar LBBAP (19.3% [95% CI, 15.0%–23.7%]) or bipolar LBBAP (16.4% [95% CI, 12.7%–20.0%]; P ≤0.005). QRS shortening was greater in LOT-CRT (29.5 [95% CI, 23.4–35.6] ms) than unipolar LBBAP (11.9 [95% CI, 6.1–17.7] ms), bipolar LBBAP (11.7 ms [95% CI, 6.4–17.0]), or BVP (18.5 [95% CI, 11.0–25.9] ms), all P ≤0.005. Compared with patients with left bundle branch block, patients with interventricular conduction delay experienced less QRS reduction ( P =0.026) but similar improvements in LV d P /d t max ( P =0.29). Bipolar LBBAP caused anodal capture in 54% of patients and resulted in less LV d P /d t max improvement than unipolar LBBAP (18.6% versus 23.7%; P <0.001). Subclassification of LBBAP capture (European Heart Rhythm Association criteria) indicated LBBAP or LV septal pacing in 27 patients (56%) and deep septal pacing in 21 patients (44%). The hemodynamic benefit of adding left ventricular coronary vein pacing to LBBAP depended on baseline QRS duration ( P =0.031) and success of LBBAP ( P <0.004): LOT-CRT provided 14.5% (5.0%–24.1%) greater LV d P /d t max improvement and 20.8 (12.8–28.8) ms greater QRS shortening than LBBAP in subjects with QRS ≥171 ms and deep septal pacing capture type. CONCLUSIONS: In a CRT cohort with advanced conduction disease, LOT-CRT and BVP provided greater acute hemodynamic benefit than LBBAP. Subjects with wider QRS or deep septal pacing are more likely to benefit from the addition of a left ventricular coronary vein lead to implement LOT-CRT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04905290.

2 July 2025 in EP Europace
Verified
Journal Article
Open access
FSFrédéric Sacher
Frédéric Sacher
ASAndrea Sarkozy
Andrea Sarkozy
HPHelmut Purerfellner
Helmut Purerfellner
ASAlexandra Steyer
Alexandra Steyer
JLJonathan Lyne
Jonathan Lyne
PPPetr Peichl
Petr Peichl
Aims: The feasibility and safety of the lattice-tip catheter for ventricular arrhythmia (VA) ablation in humans remain largely unknown. This study aimed to assess feasibility, safety profile as well as patient outcomes after VA ablation with a lattice-tip catheter in a multicentre European registry. Methods and results: All 18 European centres using the AFFERA system in September 2024 agreed to participate. Clinical, procedural, and follow-up data (minimum 3 months) were systematically collected and analysed. A total of 126 patients (18% female; mean age 59 ± 16 years) underwent VA ablation using the lattice-tip catheter during the inclusion period. Ablation indications included ventricular tachycardia (VT) in 99, premature ventricular complexes (PVCs) in 23, and ventricular fibrillation (VF) in 4 patients. Major and minor acute complications were observed in 7 (6%) and 18 (14%) procedures, respectively. They included thrombo-embolic event (n = 2), major bleeding (n = 2), ventricular fibrillation induction (n = 1), tamponade due to epicardial access (n = 1), and cardiogenic shock due to prolonged VT mapping (n = 1). Within the first month post-procedure, three patients died [from multi-organ failure (n = 2) and sepsis (n = 1)], two had worsening heart failure, one myocardial infarction, one sepsis, and one major gastro-intestinal bleeding. After a mean follow-up of 5.6 ± 3.7 months, absence of recurrence was 78% for PVC, 70% for VT, and 100% for VF. Conclusion: In this complex population with refractory VA, ablation using the lattice-tip catheter appears feasible and relatively safe. In the absence of large, randomized trials, exhaustive registry is of key importance to ensure safety and efficacy of new catheter technologies.

5 May 2026 in EP Europace
Verified
Journal Article
Open access
RSRobert D Schaller
Robert D Schaller
PFPaul Foley
Paul Foley
BCBadrinathan Chandrasekaran
Badrinathan Chandrasekaran
JLJonathan Lyne
Jonathan Lyne
MJMarek JastrzęBski
Marek JastrzęBski
ZWZachary Whinnett
Zachary Whinnett
Aims: This study aimed to determine optimal atrioventricular (AV) timing for left bundle branch area pacing (LBBAP) and optimal AV and interventricular (VV) timing for LBBAP optimized cardiac resynchronization therapy (LOT-CRT) to enhance the benefit of conduction system pacing. Methods and results: Acute measurements of LV dP/dtmax and QRS duration were collected during sweeps of AV and VV delays during paired comparison of LBBAP, LOT-CRT, and biventricular pacing (BVP) in 48 CRT-indicated patients. Optimal AV delays were selected as the vertex of a parabolic model fit to the AV sweep results, obtained independently for LV dP/dtmax and QRS duration. LBBAP, LOT-CRT, and BVP were similarly sensitive to the choice of AV delay, and 60 ms deviations from optimal AV delay resulted in an approximately 30% reduction in the haemodynamic benefits of resynchronization. Based upon LV dP/dtmax measurements, the average optimal paced AV (PAV) for LBBAP (152 ms) was significantly shorter than that for LOT-CRT (171 ms, P < 0.01) or BVP (167 ms, P = 0.01). Based upon QRS duration, the average optimal PAV for LBBAP (164 ms) was similar to that for LOT-CRT (160 ms, P = 0.52) or BVP (165 ms, P = 0.95). For each resynchronization modality, a linear regression between the patient's measured intrinsic AV conduction and their optimal AV delay provided a patient-specific AV delay, resulting in improved AV selection compared to applying a fixed AV delay to all patients. Finally, simultaneous activation (VV = 0) was best for both LOT-CRT and BVP. Conclusion: LBBAP, LOT-CRT, and BVP are similarly sensitive to AV-timing. Optimal AV delay is linearly related to intrinsic AV for each resynchronization modality. For LOT-CRT and BVP, simultaneous biventricular activation is best on average. Clinical Trial Registration information: https://clinicaltrials.gov/study/NCT04905290